ABSTRACT
Better understanding of the pathogenesis of acquired immunodeficiency syndrome (AIDS) would be greatly facilitated by a relevant animal model that uses molecularly cloned virus of defined sequence to induce the disease. Such a system would also be of great value for AIDS vaccine research. An infectious molecular clone of simian immunodeficiency virus (SIV) was identified that induces AIDS in common rhesus monkeys in a time frame suitable for laboratory investigation. These results provide another strong link in the chain of evidence for the viral etiology of AIDS. More importantly, they define a system for molecular dissection of the determinants of AIDS pathogenesis.
Subject(s)
Acquired Immunodeficiency Syndrome , Disease Models, Animal , Retroviridae Infections , Simian Immunodeficiency Virus , Animals , Antibodies, Viral/biosynthesis , Cloning, Molecular , Leukocytes, Mononuclear/microbiology , Macaca mulatta , Macrophages/microbiology , Opportunistic Infections/etiology , Retroviridae Infections/complications , Retroviridae Infections/immunology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/isolation & purification , Simian Immunodeficiency Virus/pathogenicity , Transfection , Virus ReplicationABSTRACT
The major components of the SD system have been examined in two natural populations of D. melanogaster to investigate how SD behaves and is maintained in nature and to estimate its impact and efficiency. A twofold approach was used: (1) direct measurements of segregation distortion in wild males and (2) measurement of sensitivity of wild SD (+) chromosomes to SD action. Characterization of newly isolated SD chromosomes and of a large number of SD( +) chromosomes from nature demonstrated that (1) SD can operate efficiently in the wild genome: 45% of SD/SD(+) males collected from nature had k values larger than 0.70. (2) Forty-three of 44 newly recovered SD chromosomes are of the SD-72 type, having a small pericentric inversion that maintains tight linkage among the Sd, E(SD) and Rsp loci in the SD complex. In 1956, most SD chromosomes in Madison lacked this inversion. (3) Only 12 of the 44 SD chromosomes carried a recessive lethal (compared with five of six in 1956), and many of the viable SD chromosomes were fertile as homozygotes, indicating that SD homozygotes need not have obvious reductions in fitness. (4) Among more than 500 wild chromosomes assayed for response to distortion by a strong SD, at least 40-50% were sensitive, about 33% were partially sensitive and 17% were insensitive. This frequency of sensitives is higher than in reports from some other populations. An estimated 12% of the wild chromosomes were classified as true Rsp(i) by their constellation of effects, including a special test of ability to cause self-distortion of a "suicide" chromosome, R(cn)-10. In a direct assay with R(cn)-10, an independent sample of 99 chromosomes from nature gave 30% putative Rsp(i). Thus, these populations contain in the range of 12-30% Rsp(i). (5) Chromosomes supersensitive to SD, previously described for certain laboratory stocks, were also found to coexist in nature with SD. (6) Profiles of wild chromosomes with a panel of three or four different SD testers suggest a series of allelic alternatives at the Rsp locus including supersensitive, sensitive, semisensitive and insensitive, and that loci other than Rsp may also be important in determining the effect of SD in nature.
ABSTRACT
BACKGROUND: Simple and affordable intervention strategies are needed to reduce the rate of HIV transmission from mother to infant in developing countries. Simian immunodeficiency virus (SIV) infection of newborn rhesus macaques is considered to be a useful model of human pediatric HIV infection. OBJECTIVE: To investigate whether short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration can protect newborn rhesus macaques against perinatal SIV infection. DESIGN AND METHODS: Eight newborn macaques were inoculated orally with highly virulent SIVmac within the first 3 days of life. Four of these animals were untreated controls. The other four animals were given one dose of PMPA (30 mg/kg subcutaneously) 4 h before oral SIV inoculation, and were then given a second and final dose of PMPA 24 h later. RESULTS: All four untreated control animals were persistently SIV-positive within 2 weeks after virus inoculation. In contrast, no virus could be detected in the four animals that received two doses of PMPA; these animals were seronegative and healthy at 10 months. CONCLUSIONS: Two doses of PMPA prevented SIV infection of newborn macaques. Our data suggest that short-term administration of PMPA to HIV-infected pregnant women at the onset of labor and to their newborns after delivery may reduce the rate of intrapartum HIV transmission.
Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/administration & dosage , Organophosphonates , Organophosphorus Compounds/administration & dosage , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus , Adenine/administration & dosage , Animals , Animals, Newborn , Antibodies, Viral/blood , Dose-Response Relationship, Drug , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Tenofovir , ViremiaABSTRACT
The purpose of this study was to determine whether rhesus monkeys of Chinese origin are suitable for studies of mucosal lentivirus transmission by comparing the relative ability of these animals and rhesus macaques of Indian origin to become infected by vaginal (IVAG) inoculation with SIVmac251. In addition, we sought to test the hypothesis that differences in viral load during the first few weeks after inoculation were due to the relative strength of the anti-SIV immune responses in the two populations of rhesus macaques. Significant difference was not observed between the number of Indian and Chinese origin monkeys that were infected after IVAG SIV inoculation in this study. For 8-9 weeks after infection there was considerable overlap in the range of viral loads among the Indian and Chinese animals and the variation among the Indian origin animals was greater than the variation among the Chinese origin monkeys. By 6 weeks postinfection, viral loads in SIV-infected Chinese origin monkeys tended to be at the lower end of the range of viral loads observed in SIV-infected Indian origin monkeys. The strength of the anti-SIV antibody response was also more variable in the Indian origin rhesus macaques, but at 6-8 weeks postinfection, Chinese and Indian origin rhesus macaques had similar titers of anti-SIV antibodies. Microsatellite allele frequencies differed between Chinese and Indian rhesus macaques; however, the majority of alleles present in Indian-origin animals were also found in Chinese macaques. Together these results show that host factors, other than geographic origin, determine the ability of a rhesus macaque to be infected after IVAG SIV exposure and that geographic origin does not predict the viral load of SIV-infected animals during the first 8-9 weeks after IVAG inoculation.
Subject(s)
Antibodies, Viral/immunology , Macaca mulatta/genetics , Simian Acquired Immunodeficiency Syndrome/genetics , Simian Immunodeficiency Virus/physiology , Viral Load , Animals , Antibodies, Viral/blood , Cells, Cultured , China , Female , India , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/virology , Macaca mulatta/immunology , Macaca mulatta/virology , RNA, Viral/blood , Simian Acquired Immunodeficiency Syndrome/blood , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/isolation & purification , Titrimetry , Vagina/virologyABSTRACT
As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIVmac239 gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (i.v.) infection with pathogenic SIVmac isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIVmac239 and another genetically similar, uncloned isolate, SIVmac251. Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after i.v. inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIVmac251, but not those challenged with SIVmac239, the cell-free infectious virus load in plasma of vSIVgp160-primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.
Subject(s)
Gene Products, env/administration & dosage , Gene Products, env/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/immunology , Viral Vaccines/administration & dosage , Animals , Cells, Cultured , HeLa Cells , Humans , Immunization , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/microbiology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Vaccinia virus/immunology , Viral Vaccines/immunologyABSTRACT
Retroviral envelope glycoproteins interact with cell receptors and are targets for antiviral immune responses in infected hosts. Macaque simian immunodeficiency virus (SIVmac) is a T-lymphocytopathic lentivirus which causes an AIDS-like disease in rhesus macaques. The envelope gene of SIVmac encodes a precursor glycoprotein (gp160) which is cleaved into an external domain (gp130) and a transmembrane domain (gp32). To investigate the functional and immunological properties of the SIV external envelope glycoprotein, we have used genetically engineered mammalian cells to produce recombinant gp130 (rgp130). The rgp130 has the appropriate molecular weight, is glycosylated, and has native conformation as determined by binding to the cell receptor for SIV, the CD4 antigen. Rhesus macaques immunized with purified rgp130 formulated in muramyl dipeptide adjuvant generated high titers of antienvelope antibodies. Antibodies from these macaques were tested for in vitro virus neutralization; very low or undetectable levels of neutralization were observed. In contrast, neutralizing antibodies were readily detected in sera from goats immunized with rgp130. With respect to cell-mediated immunity, proliferative responses to rgp130 were demonstrated in peripheral blood monocyte cells (PBMC) from macaques immunized with the recombinant glycoprotein as well as in PBMC from SIV-infected animals. These results show that rgp130 is functional and immunogenic; the potential of rgp130 for protective immunization remains to be determined.
Subject(s)
Gene Products, env/chemistry , Genetic Engineering , Simian Immunodeficiency Virus/chemistry , Animals , Antibodies, Viral/biosynthesis , Base Sequence , CD4 Antigens/metabolism , CHO Cells , Cloning, Molecular , Cricetinae , Gene Products, env/genetics , Gene Products, env/immunology , Genetic Vectors , Goats , Lymphocyte Activation , Macaca mulatta , Molecular Sequence Data , Protein Binding , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunologyABSTRACT
Simian immunodeficiency virus (SIV) is a designation for a group of related but unique lentiviruses identified in several primate species. A viral isolate from a rhesus macaque (i.e., SIVmac) causes a fatal AIDS-like disease in experimentally infected macaques, and several infectious molecular clones of this virus have been characterized. This report presents the complete nucleotide sequence of molecularly cloned SIVmac1A11, and comparisons are made with the sequence of molecularly cloned SIVmac239. SIVmac1A11 has delayed replication kinetics in lymphoid cells but replicates as well as uncloned SIVmac in macrophage cultures. Macaques infected with virus from the SIVmac1A11 clone develop antiviral antibodies, but virus does not persist in peripheral blood mononuclear cells and no disease signs are observed. SIVmac239 infects lymphoid cells, shows restricted replication in cultured macrophages, and establishes a persistent infection in animals that leads to a fatal AIDS-like disease. Both viruses are about 98% homologous at the nucleotide sequence level. In SIVmac1A11, the vpr gene as well as the transmembrane domain of env are prematurely truncated, whereas the nef gene of SIVmac239 is prematurely truncated. Sequence differences are also noted in variable region 1 (V1) in the surface domain of the env gene. The potential implications of these and other sequence differences are discussed with respect to the phenotypes of both viruses. This animal model is critically important for investigating the roles of specific viral genes in viral/host interactions that cannot be studied in individuals infected with the human immunodeficiency virus (HIV).
Subject(s)
Simian Immunodeficiency Virus/pathogenicity , Amino Acid Sequence , Animals , Cloning, Molecular , Genes, Viral/genetics , Genes, Viral/physiology , Molecular Sequence Data , Sequence Homology, Nucleic Acid , Simian Immunodeficiency Virus/geneticsABSTRACT
Simian immunodeficiency virus (SIV) infection of newborn macaques is a useful animal model to explore novel strategies to reduce perinatal human immunodeficiency virus (HIV) infection. The availability of two easily distinguishable virus isolates, SIVmac251 and the simian/human immunodeficiency virus chimera SHIV-SF33, allows tracing the source of infection following inoculation with both viruses by different routes. In the present study, we evaluated the efficacy of pre- and postinoculation treatment regimens with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) to protect newborn macaques against simultaneous oral SIVmac251 and intravenous SHIV-SF33 inoculation. Untreated newborns became persistently infected following virus inoculation. When three pregnant macaques were given a single subcutaneous dose of PMPA 2 hr before cesarean section, their newborns became SIV-infected following SIV and SHIV inoculation shortly after birth. In contrast, when four newborn macaques were inoculated simultaneously with SIV and SHIV, and started immediately on PMPA treatment for 2 weeks, only one animal became persistently SIV-infected; the remaining three PMPA-treated newborns, however, had some evidence of an initial transient virus infection but were seronegative and healthy at 8 months of age. Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV.
Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/therapeutic use , Organophosphonates , Organophosphorus Compounds/therapeutic use , Simian Acquired Immunodeficiency Syndrome/prevention & control , Adenine/administration & dosage , Adenine/blood , Adenine/therapeutic use , Animals , Animals, Newborn , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/blood , Antibodies, Viral/blood , Cesarean Section , Chimera , Drug Administration Schedule , Female , HIV/drug effects , HIV/genetics , HIV/immunology , HIV Infections/prevention & control , Humans , Macaca mulatta , Organophosphorus Compounds/administration & dosage , Organophosphorus Compounds/blood , Pregnancy , RNA, Viral/blood , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/drug effects , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Tenofovir , Treatment OutcomeSubject(s)
Acquired Immunodeficiency Syndrome/etiology , Disease Models, Animal , Simian Acquired Immunodeficiency Syndrome/virology , Acquired Immunodeficiency Syndrome/virology , Animals , Animals, Newborn , Humans , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus/drug effects , Zidovudine/therapeutic useSubject(s)
AIDS Vaccines , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/pathogenicity , AIDS Vaccines/adverse effects , Animals , Animals, Newborn , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Acquired Immunodeficiency Syndrome/transmission , Vaccines, Attenuated/adverse effects , VirulenceSubject(s)
Antibodies, Viral/immunology , Immunization/methods , Immunoglobulin Isotypes/immunology , Macaca mulatta/immunology , Simian Immunodeficiency Virus/immunology , Administration, Oral , Animals , Antibodies, Viral/classification , Female , Immunization, Secondary , Injections, Intramuscular , Simian Acquired Immunodeficiency Syndrome/immunology , Trachea , Vagina/immunologySubject(s)
Feline Acquired Immunodeficiency Syndrome/prevention & control , Immunodeficiency Virus, Feline/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/immunology , Vaccination , Viral Vaccines/immunology , Animals , Cats , Disease Models, Animal , Female , Gene Products, env/immunology , Injections, Intravenous , Macaca mulatta/immunology , Male , Vaccines, Attenuated/immunology , Vaccines, Inactivated/immunology , Vaccines, Synthetic/immunology , VaginaSubject(s)
Retroviruses, Simian/immunology , SAIDS Vaccines/immunology , Simian Immunodeficiency Virus/immunology , Viral Vaccines/immunology , AIDS Vaccines , Animals , Gene Products, env/immunology , Gene Products, nef/genetics , Gene Products, nef/immunology , HIV-1/immunology , Humans , Simian Immunodeficiency Virus/pathogenicity , nef Gene Products, Human Immunodeficiency VirusABSTRACT
The significance of infection of mononuclear phagocytes by immunodeficiency lentiviruses of primates is not clearly established. To explore the relationship of macrophage tropism and pathogenesis, conditions to culture and infect monocyte-derived macrophages from rhesus macaques were established and the growth properties of two molecular proviral clones of simian immunodeficiency virus (SIVmac) were studied. Rhesus macrophages supported productive infection of the nonpathogenic SIVmac-1A11 clone; extensive cytopathology characterized by formation of multinucleated giant cells and release of particle-associated reverse transcriptase activity in culture supernatant were observed. In contrast, the pathogenic SIVmac-239 did not establish a productive infection of macrophages and no cytopathology was observed. Both SIVmac-1A11 and SIVmac-239 replicated and induced cytopathic effects in cultures of rhesus peripheral blood lymphocytes and the Cemx174 lymphoid cell line. These results, together with the previously published reports on the pathogenic potential of these two clones of SIVmac, suggest that macrophage tropism measured in vitro does not correlate with in vivo virulence.
Subject(s)
Macrophage Activation , Macrophages/microbiology , Simian Immunodeficiency Virus/pathogenicity , Animals , Cell Adhesion , Cloning, Molecular , Cytopathogenic Effect, Viral , In Vitro Techniques , Macaca mulatta , Macrophages/enzymology , RNA-Directed DNA Polymerase/metabolism , Simian Acquired Immunodeficiency Syndrome/etiology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/ultrastructure , Transfection , Virus ReplicationABSTRACT
Early hematologic changes were studied over a 14 day period in three groups of six rhesus macaques intravenously infected with pathogenic and nonpathogenic isolates of SIVmac. Abnormalities in blood included a mild blood loss anemia, sporadic lymphopenia, and variable CD4+ and CD8+ T lymphocyte numbers. Prominent bone marrow findings in macaques inoculated with pathogenic uncloned SIVmac and molecularly cloned pathogenic SIVmac-239 were hypercellularity, myeloid and megakaryocytic hyperplasia, and lymphoid aggregates. Infrequent mild morphologic abnormalities were present in macaques infected with a nonpathogenic molecular clone, SIVmac-1A11.
Subject(s)
Simian Acquired Immunodeficiency Syndrome/blood , Simian Immunodeficiency Virus/pathogenicity , Anemia/etiology , Animals , Blood Cell Count , Bone Marrow/pathology , CD4-Positive T-Lymphocytes/immunology , CD8 Antigens , Cloning, Molecular , Lymphopenia/etiology , Macaca mulatta , Male , Simian Acquired Immunodeficiency Syndrome/etiology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/genetics , T-Lymphocyte Subsets/immunology , Time FactorsABSTRACT
The extent of virus replication, tissue distribution, localization of virus within tissues, and the presence of pathological lesions was examined early after experimental infection of rhesus monkeys with simian immunodeficiency virus (SIV). Three strains of SIV were used: molecularly cloned pathogenic SIVmac239; molecularly cloned nonpathogenic SIVmac1A11; and uncloned pathogenic SIVmac. The major targets of infection in all animals at 2 weeks postinoculation were the thymus and spleen. The distribution of virus within lymphoid organs varied with the viral inoculum: nonpathogenic SIVmac1A11 was present primarily within lymphoid follicles and in the thymic cortex; SIVmac239 was present primarily within periarteriolar lymphoid sheaths in the spleen, the paracortex of lymph nodes, and the medulla of the thymus; uncloned SIVmac was present in all these areas but tended to parallel the distribution of SIVmac239. Animals inoculated with nonpathogenic SIVmac1A11 had fewer SIV-positive cells by in situ hybridization and after 13 weeks postinoculation, virus was undetectable in any tissue from these animals. No significant pathological abnormalities were recognized in animals inoculated with this nonpathogenic virus. In contrast, nearly half of the animals inoculated with either SIVmac or SIVmac239 developed significant pathological lesions, including opportunistic infections by 13 weeks postinoculation, highlighting the virulence of these viruses. Our results indicate marked differences in tissue distribution between pathogenic and nonpathogenic molecular clones of SIV during the acute phase of infection. The most striking differences were the absence of SIVmac1A11 from the central nervous system and thymic medulla. The prominent early involvement of the thymus suggests that infection of this organ is a key event in the induction of immune suppression by SIV.
Subject(s)
Simian Acquired Immunodeficiency Syndrome/microbiology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/pathogenicity , Animals , Antibodies, Viral/analysis , Antigens/analysis , Blood , Cloning, Molecular , Macaca mulatta , Male , Prospective Studies , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/isolation & purificationABSTRACT
Assays that use rhesus macaque whole blood and an antigen capture enzyme-linked immunosorbent assay for the simian immunodeficiency virus (SIV) p27 core protein were developed for the isolation of SIV from the blood of infected animals, the titration of infectivity of SIV inocula, and the quantitation of virus neutralizing antibodies in serum. These assays required small amounts of whole blood, were adaptable to a microtiter format, and used substrates mainly of rhesus macaque origin.
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Simian Acquired Immunodeficiency Syndrome/microbiology , Simian Immunodeficiency Virus/isolation & purification , Animals , Antibodies, Viral , Antigens, Viral/blood , Evaluation Studies as Topic , Gene Products, gag/immunology , Macaca mulatta , Neutralization Tests , Simian Acquired Immunodeficiency Syndrome/blood , Simian Immunodeficiency Virus/immunologyABSTRACT
We used the rhesus macaque model of heterosexual human immunodeficiency virus (HIV) transmission to test the hypothesis that in vitro measures of macrophage tropism predict the ability of a primate lentivirus to initiate a systemic infection after intravaginal inoculation. A single atraumatic intravaginal inoculation with a T-cell-tropic molecular clone of simian immunodeficiency virus (SIV), SIVmac239, or a dualtropic recombinant molecular clone of SIV, SIVmac239/1A11/239, or uncloned dualtropic SIVmac251 or uncloned dualtropic simian/human immunodeficiency virus (SHIV) 89.6-PD produced systemic infection in all rhesus macaques tested. However, vaginal inoculation with a dualtropic molecular clone of SIV, SIVmac1A11, resulted in transient viremia in one of two rhesus macaques. It has previously been shown that 12 intravaginal inoculations with SIVmac1A11 resulted in infection of one of five rhesus macaques (M. L. Marthas, C. J. Miller, S. Sutjipto, J. Higgins, J. Torten, B. L. Lohman, R. E. Unger, H. Kiyono, J. R. McGhee, P. A. Marx, and N. C. Pedersen, J. Med. Primatol. 21:99-107, 1992). In addition, SHIV HXBc2, which replicates in monkey macrophages, does not infect rhesus macaques following multiple vaginal inoculations, while T-cell-tropic SHIV 89.6 does (Y. Lu, P. B. Brosio, M. Lafaile, J. Li, R. G. Collman, J. Sodroski, and C. J. Miller, J. Virol. 70:3045-3050, 1996). These results demonstrate that in vitro measures of macrophage tropism do not predict if a SIV or SHIV will produce systemic infection after intravaginal inoculation of rhesus macaques. However, we did find that the level to which these viruses replicate in vivo after intravenous inoculation predicts the outcome of intravaginal inoculation with each virus.